National Health (Price and Special Patient Contribution) Amendment Determination 2023 (No. 2)

Administered by Department of Health, Disability and Ageing

Legislation au F2023L00387 Not in force Legislative Instrument

Legislation content

EXPLANATORY STATEMENT

NATIONAL HEALTH ACT 1953

NATIONAL HEALTH (PRICE AND SPECIAL PATIENT CONTRIBUTION) AMENDMENT DETERMINATION 2023 (No. 2)

PB 29 of 2023

 

Authority

This legislative instrument, made under section 85B of the National Health Act 1953 (the Act), amends the National Health (Price and Special Patient Contribution) Determination 2022 (PB 98 of 2022) (the Principal Determination).

Subsections 85B(2), (3) and (4) of the Act provide for the Minister to determine, respectively, determined prices, claimed prices and the circumstances in which the Commonwealth will pay a special patient contribution. The Principal Determination contains determinations of these matters.

Variation and revocation

Unless there is an express power to revoke or vary PB 98 of 2022 cited in this instrument and explanatory statement, subsection 33(3) of the Acts Interpretation Act 1901 is relied upon to revoke or vary PB 98 of 2022.

Purpose

The Act provides for the Minister and the responsible person to agree a price that is taken to be the appropriate maximum price of a brand of a pharmaceutical item for the purposes of Part VII of the Act (section 85AD). Section 85B of the Act applies if the Minister and the responsible person have been unable to reach an agreement on a price for the pricing quantity. Whether or not an agreement is made for the pricing quantity, section 85B also applies if the responsible person is dissatisfied with the proportional ex-manufacturer prices that will apply to other pack quantities.

Subsection 85B(2) provides that the Minister may determine, by reference to the pricing quantity of a brand of a pharmaceutical item, an amount that is taken to be the appropriate maximum price of the brand for the purposes of Part VII of the Act. This is termed the ‘Determined Price’ in this Determination.

Subsection 85B(3) provides that the Minister may determine, by reference to a pack quantity of a brand of the pharmaceutical item, an amount that is taken to be the price claimed by the responsible person for the pack quantity of the brand, for the purposes of Part VII of the Act. This is termed the ‘Claimed Price’ in this Determination.

The Determined Price is the Approved Ex-Manufacturer Price (AEMP) and is used as the basis for working out the Commonwealth price for the brand of the pharmaceutical item (section 98B of the Act); for pack quantities other than the pricing quantity, the proportional ex-manufacturer price (PEMP) is used as the basis. Approved pharmacists are entitled to receive a payment from the Commonwealth equal to the Commonwealth price less the applicable patient co-payment (section 99 of the Act).

The difference between the Responsible Person’s Commonwealth price for a pack quantity (i.e, the price that would be the Commonwealth price if the responsible person’s claimed price had become the approved ex-manufacturer price or the proportional ex-manufacturer price for that pack quantity) and the Commonwealth price for the pack quantity is defined in subsection 85B(5) of the Act as the special patient contribution. An approved pharmacist may charge a patient an amount equal to the special patient contribution, in addition to any other amount that may be charged (subsection 87(2A) of the Act).

Subsection 85B(4) of the Act provides that the Minister may determine the circumstances in which the Commonwealth is to pay the Special Patient Contribution for a brand. In such cases, the Commonwealth payment to the pharmacist is increased by the amount of the special patient contribution (subsection 99(2AA) of the Act) and the pharmacist may not charge the patient this amount (subsection 87(2A) of the Act). 

The purpose of making subsection 85B(4) determinations is to enable patients for whom the base-priced brands (the ones without a special patient contribution) are not suitable, to obtain the higher priced brand (the one with the special patient contribution) without the need to pay the higher price. In such cases the Commonwealth pays the special patient contribution.

This instrument (the Determination) amends the Principal Determination by providing reduced determined and claimed prices resulting from the application of statutory price reductions and price discosure effective from 1 April 2023.

In respect of salbutamol, the Determination provides a reduced a claimed price for one brand as requested by the responsible person, and which will have the effect of lowering the applicable patient co-payment. The amendments provided by this Determintion take effect on 1 April 2023. 

Consultation

This Determination affects certain responsible persons with medicines listed on the PBS. Before a pharmaceutical benefit is listed on the PBS, and from time to time thereafter, price negotiations occur between the Responsible Person and the Minister for the purpose of reaching a price agreement for section 85AD of the Act. If the Minister and the Responsible Person do not agree on a price, further consultation occurs with the Responsible Person, and thereafter the Minister determines the price that will be the approved ex-manufacturer price for the brand. The Minister also determines the corresponding price claimed by the responsible person which is used to calculate the special patient contribution that will apply to the brand.

All responsible persons with listed brands which are subject to price disclosure reductions under section 99ADHC of the Act were informed of the changes through information published on the pbs.gov.au website in December 2022.

All responsible persons with listed brands subject to statutory price reductions including catch-up price reduction under section 99ACN of the Act were informed of the eligible brands and indicative prices through information published on the pbs.gov.au website in July 2022.

The responsible person affected by this Determination for salbutamol made a submission about the claimed price the Minister should determine in relation to their brands. The responsible person was advised of the delegate’s intention to determine in accordance with their request. No further response from the affected responsible person were received in response to this notification.

 

No additional consultation with experts was undertaken regarding this Determination because consultation with affected responsible person, which informed the making of this Determination, drew on the knowledge of persons with relevant expertise.

A provision by provision description of the Determination is contained in the Attachment.

This Determination commences on 1 April 2023.

This Determination is a legislative instrument for the purposes of the Legislation Act 2003.

 


ATTACHMENT  

 

PROVISION BY PROVISION DESCRIPTION OF THE NATIONAL HEALTH (PRICE AND SPECIAL PATIENT CONTRIBUTION) AMENDMENT DETERMINATION 2023 (No.2)

(PB 29 of 2023)

Section 1   Name of Determination

This section provides that the Determination is the National Health (Price and Special Patient Contribution) Amendment Determination 2023 (No. 2) and may also be cited as PB 29 of 2023.

Section 2   Commencement

This section provides that the Determination commences on 1 April 2023.

Section 3   Amendment of the National Health (Price and Special Patient Contribution) Determination 2022 (PB 98 of 2022).

This section provides that Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2022 (PB 98 of 2022).

Schedule 1 Amendments commencing 1 April 2023

Schedule 1 sets out the amendments to the Principal Determination which commence on 1 April 2023.

SUMMARY OF CHANGES

SCHEDULE 1

 

Brands with reduced brand premiums

 

Betamethasone

Cream 200 micrograms (as valerate) per g, 100 g

Betnovate 1/5

 

Cream 200 micrograms (as valerate) per g, 100 g

Celestone M

 

Cream 500 micrograms (as dipropionate) per g, 15 g

Diprosone

 

Ointment 500 micrograms (as dipropionate) per g, 15 g

Diprosone

 

 

 

Brimonidine

Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL

Alphagan

 

 

 

Brinzolamide

Eye drops 10 mg per mL, 5 mL

Azopt

 

 

 

Carbamazepine

Tablet 100 mg

Tegretol 100

 

Tablet 200 mg

Tegretol 200

 

 

 

Carmellose

Eye drops containing carmellose sodium 5 mg per mL, single dose units 0.4 mL, 30

Cellufresh

 

Eye drops containing carmellose sodium 10 mg per mL, single dose units 0.4 mL, 30

Celluvisc

 

 

 

Cyproterone

Tablet containing cyproterone acetate 50 mg

Androcur

 

Tablet containing cyproterone acetate 100 mg

Androcur‑100

 

 

 

Eprosartan

Tablet 400 mg (as mesilate)

Teveten

 

Tablet 600 mg (as mesilate)

Teveten

 

 

 

Fluticasone propionate

Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC‑free formulation)

Flixotide

 

Pressurised inhalation containing fluticasone propionate 250 micrograms per dose, 120 doses (CFC‑free formulation)

Flixotide

 

Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms per dose, 60 doses

Flixotide Junior Accuhaler

 

Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms per dose, 60 doses

Flixotide Accuhaler

 

 

 

Gliclazide

Tablet 60 mg (modified release)

Diamicron 60mg MR

 

 

 

Ketoprofen

Capsule 200 mg (sustained release)

Orudis SR 200

 

 

 

Lansoprazole

Tablet 30 mg (orally disintegrating)

Zoton FasTabs

 

 

 

Levothyroxine

Tablet containing 50 micrograms anhydrous levothyroxine sodium

Oroxine

 

Tablet containing 75 micrograms anhydrous levothyroxine sodium

Oroxine

 

Tablet containing 100 micrograms anhydrous levothyroxine sodium

Oroxine

 

Tablet containing 200 micrograms anhydrous levothyroxine sodium

Oroxine

 

 

 

Medroxyprogesterone

Tablet containing medroxyprogesterone acetate 5 mg

Provera

 

 

 

Mercaptopurine

Tablet containing mercaptopurine monohydrate 50 mg

Purinethol

 

 

 

Naproxen

Tablet 1 g (sustained release)

Naprosyn SR1000

 

Tablet 750 mg (sustained release)

Naprosyn SR750

 

Tablet containing naproxen sodium 550 mg

Anaprox 550

 

 

 

Naratriptan

Tablet 2.5 mg (as hydrochloride)

Naramig

 

 

 

Norethisterone with ethinylestradiol

Pack containing 21 tablets 1 mg‑35 micrograms and 7 inert tablets

Brevinor-1

 

 

 

Omeprazole

Tablet 20 mg (as magnesium)

Losec Tablets

 

 

 

Paraffin

Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g

Refresh Night Time

 

 

 

Prednisolone

Oral solution 5 mg (as sodium phosphate) per mL, 30 mL

Redipred

 

 

 

Raloxifene

Tablet containing raloxifene hydrochloride 60 mg

Evista

 

 

 

Rasagiline

Tablet 1 mg (as mesilate)

Azilect

 

 

 

Salbutamol

Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC‑free formulation)

Asmol CFC‑Free with dose counter

 

 

 

Verapamil

Tablet containing verapamil hydrochloride 80 mg

Isoptin

 

Tablet containing verapamil hydrochloride 180 mg (sustained release)

Isoptin 180 SR

 

Tablet containing verapamil hydrochloride 240 mg (sustained release)

Isoptin SR

 

 

 

Statement of Compatibility with Human Rights

Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011

National Health (Price and Special Patient Contribution) Amendment Determination 2023 (No. 2) (PB 29 of 2023)

This legislative instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

 

Overview of the Legislative Instrument

This legislative instrument, made under section 85B of the National Health Act 1953 (the Act), amends the National Health (Price and Special Patient Contribution) Determination 2022 (the Principal Determination), which provides for price determinations in relation to brands of pharmaceutical items listed on the Pharmaceutical Benefits Scheme (PBS) for which the Minister and the responsible person have not been able to make a price agreement. It also provides for the circumstances in which the Commonwealth will pay the special patient contribution resulting from these price determinations. This instrument amends the Principal Determination by providing reduced determined prices and/or claimed prices of specified brands of pharmaceutical items. These changes take effect on 1 April 2023. 

 

Human rights implications

This legislative instrument engages Articles 2 and 12 of the International Covenant on Economic, Social and Cultural Rights by assisting with the progressive realisation by all appropriate means of the right of everyone to the enjoyment of the highest attainable standard of physical and mental health.

The PBS is a benefit scheme which assists with advancement of this human right by providing for subsidised access by patients to medicines. The reduction of determined prices and/or claimed prices to the specified brands of pharmaceutical items will have the effect of lowering the existing brand price premiums payable by patients. This will improve the affordability of these brands for patients.

It is longstanding Government policy that pharmaceutical companies are only able to charge brand price premiums where there is at least one premium-free brand of that medicine available through the PBS. All brands subsidised by the PBS are evaluated by the Therapeutic Goods Administration (TGA) for quality and safety and determined to be bioequivalent, which means they are clinically equivalent and work in the same way. Increasing or imposing brand price premiums are therefore unlikely to result in negative financial impact for patients, therefore ensuring their rights to social security are maintained. The recommendatory role of the Pharmaceutical Benefits Advisory Committee (PBAC) ensures that decisions about subsidised access to medicines on the PBS are evidence-based.

 

Conclusion

This legislative instrument is compatible with human rights because it advances the protection of human rights.

Nikolai Tsyganov

 Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health and Aged Care

Overview

The National Health (Price and Special Patient Contribution) Amendment Determination 2023 (No. 2) (PB 29 of 2023) was enacted to amend the National Health (Price and Special Patient Contribution) Determination 2022 (PB 98 of 2022) made under section 85B of the National Health Act 1953. This amendment was introduced to address the need for updated price determinations for pharmaceutical items listed on the Pharmaceutical Benefits Scheme (PBS). These amendments are effective from 1 April 2023 and primarily involve reduced determined and claimed prices for certain pharmaceutical brands resulting from statutory price reductions and price disclosure. The objective of these amendments is to ensure that patients have affordable access to necessary medications by reducing the financial burden associated with brand price premiums. This legislative instrument was made by the Minister for Health and Aged Care and is in accordance with the authority granted by the National Health Act 1953. The policy objective of the amendment is to enable patients to access necessary medications at reduced prices, thereby improving the affordability and accessibility of essential pharmaceutical items listed on the PBS. The determination ensures that brand price premiums are only imposed where there is at least one premium-free brand available, aligning with the Government's policy to support equitable access to healthcare.

Scope and Application

The National Health (Price and Special Patient Contribution) Amendment Determination 2023 (No. 2) amends the National Health (Price and Special Patient Contribution) Determination 2022 under section 85B of the National Health Act 1953. This legislation applies to pharmaceutical brands listed on the Pharmaceutical Benefits Scheme (PBS) where the Minister and the responsible person have not reached a price agreement. Specifically, it provides for the determination of prices for pharmaceutical items and the circumstances under which the Commonwealth will pay the special patient contribution. The determination of these prices affects the affordability of these pharmaceutical items for patients, thereby impacting the accessibility of healthcare services. The amendments made by this Determination, which include reduced determined and claimed prices, take effect on 1 April 2023. The application of this Act is national, with its provisions extending across the Commonwealth of Australia, affecting entities such as pharmaceutical companies and patients who rely on the PBS for subsidised access to medicines. There are no specific exclusions or exemptions mentioned in the text, although the application is contingent upon the prices not being agreed upon by the Minister and the responsible person. Subordinate instruments, such as this Determination, extend and specify the application of the primary Act by providing detailed price determinations and adjustments as necessary.

Key Provisions

The National Health (Price and Special Patient Contribution) Amendment Determination 2023 (No. 2) (PB 29 of 2023) amends the National Health (Price and Special Patient Contribution) Determination 2022 (PB 98 of 2022) (section 3). This amendment introduces reduced determined and claimed prices for specified brands of pharmaceutical items listed on the Pharmaceutical Benefits Scheme (PBS) effective from 1 April 2023 (Schedule 1). The primary changes involve the reduction of prices for various brands, including betamethasone, carmellose, fluticasone propionate, and many others (Schedule 1). Additionally, for salbutamol, the Determination provides a reduced claimed price as requested by the responsible person, which will lower the applicable patient co-payment (Schedule 1). The Act imposes several obligations on the parties it governs. The Minister for Health is responsible for determining the appropriate maximum price of a brand of a pharmaceutical item when an agreement cannot be reached with the responsible person (section 85B(2)). The responsible person, typically the pharmaceutical company, is required to submit pricing information and engage in negotiations with the Minister (section 85AD). If a responsible person is dissatisfied with the proportional ex-manufacturer prices for other pack quantities, the Minister may also determine the claimed price for those pack quantities (section 85B(3)). Furthermore, the Minister determines the circumstances under which the Commonwealth will pay the special patient contribution, ensuring that patients who require higher-priced brands do not bear the full cost (section 85B(4)). Breach of the provisions of the Act or the Determination may lead to various consequences. Although the Determination itself does not specify penalties, the Act under which it is made outlines potential civil and criminal penalties for non-compliance. For instance, under section 114 of the National Health Act 1953, an offence is established for knowingly making a false or misleading statement in relation to a pharmaceutical benefit. This offence carries a maximum penalty of 500 penalty units (currently AUD 56,050). Additionally, section 122 of the Act addresses the potential for misleading or deceptive conduct, which can attract penalties of up to 1,000 penalty units (AUD 112,100) for individuals and significantly higher amounts for corporations. These provisions underscore the importance of compliance with the pricing and contribution determinations set out in the Act and the Determination.

Legal classification tags

Area of Law
Health Law
Instrument
Determination
Concepts
Definitions & Interpretation
Offence Provisions
Regulatory Standards

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.